ÐÇ¿Õ´«Ã½

COVID-19 Variants

Much of the uncertainty of the COVID-19 pandemic focused around new virus variants. In the last year, at least four prominent COVID-19 variants were identified. While the Brazil and South Africa variants did not have a direct impact on Utah, the Delta variant caused more severe disease and steadily drove up daily positive cases and ICU admissions at U of U ÐÇ¿Õ´«Ã½.

During the peak of Delta (mid-September 2021), U of U ÐÇ¿Õ´«Ã½ saw:

• 73 daily positive COVID-19 infections
• 79 patients hospitalized for COVID-19

In December 2021, Omicron became the next predominant variant in the U.S. and quickly made its way to Utah for another surge. Omicron, identified as more transmissible and contagious than Delta, once again put a strain on health care systems across the country and caused a heightened demand for COVID-19 testing. Because of this, U of U ÐÇ¿Õ´«Ã½ saw more hospitalizations than with any other previous variant. However, ICU admissions were less than half during the Delta surge due to Omicron causing much less severe disease.

During the peak of Omicron (mid-January 2022), U of U ÐÇ¿Õ´«Ã½ saw:

• 448 daily positive COVID-19 infections
• 141 patients hospitalized for COVID-19

During both surges, COVID-19 vaccines helped prevent infection, hospitalization, and death. Though less effective at preventing infection (and breakthrough infection), the vaccines have been extremely effective in preventing hospitalization and death.

COVID-19 Vaccines

Several major milestones were achieved over the last year with COVID-19 vaccines. COVID-19 vaccines became available for , and full licensure was granted to both and Moderna COVID-19 vaccines. Additionally, COVID-19 were authorized for anyone ages 12 and older to further protect them from severe disease and hospitalization.

At U of U ÐÇ¿Õ´«Ã½, COVID-19 vaccines and booster shots were administered at all community health centers. In the last year, U of U ÐÇ¿Õ´«Ã½ administered at least 150,370 COVID-19 vaccinations, including:

• 9,400 children (5 to 17 years)
• 25,900 booster shots

Since receiving COVD-19 vaccines at U of U ÐÇ¿Õ´«Ã½, nearly 190,300 total vaccinations have been administered.

Treatments

More potential relief for SARS-CoV-2 infection became available to patients at U of U ÐÇ¿Õ´«Ã½ over the last year. While not as effective as COVID-19 vaccines, these COVID-19 treatments help reduce a person’s risk of becoming sicker and help those who may be more vulnerable to severe disease from the virus. Current COVID-19 treatments include:

• (mAb) therapies for certain individuals in Utah. However, only one monoclonal antibody therapy () effectively works against the Omicron variant.
• is the first COVID-19 antiviral pill available by prescription for people ages 12 years and older.
• Remdesivir, an antiviral infusion, is given in an outpatient setting.
• , a pre-exposure prophylaxis monoclonal antibody, was authorized by the FDA in late 2021 for certain individuals.

Testing

U of U ÐÇ¿Õ´«Ã½ saw a demand for COVID-19 testing during the Delta and Omicron surges. At the peak of Delta, the health system tested about 250 patients a day in early September. However, during the Omicron surge, COVID-19 testing at U of U ÐÇ¿Õ´«Ã½ exceeded its testing capacity because of how contagious and transmissible Omicron became. At the peak of Omicron, test volumes reached more than 350 a day in mid-January.

At U of U ÐÇ¿Õ´«Ã½:

• More than 65,500 COVID-19 tests were collected in the last year (March 2021 – February 2022).
• Nearly 167,600 COVID-19 tests have been collected since testing began in March 2020.